Corpus Intelligence IC Memo — PAOLI HOSPITAL 2026-04-26 03:50 UTC
IC Memo — PAOLI HOSPITAL
Investment Committee Memorandum | PA | 249 beds | Grade C | EBITDA uplift $28.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PAOLI HOSPITAL

CCN 390153 | CHESTER, PA | 249 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PAOLI HOSPITAL is a 249-bed suburban community hospital in CHESTER, PA with $383.3M in net patient revenue and a -7.5% operating margin. The hospital serves a payer mix of 37.2% Medicare, 0.8% Medicaid, and 62.0% commercial.

Thesis: Undervalued. Our ML models identify $28.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -7.5% to -0.1% (+736bps).

Net Revenue HCRIS$383.3M
Current EBITDA COMPUTED$-28.7M
Operating Margin COMPUTED-7.5%
Occupancy HCRIS79.3%
Revenue / Bed COMPUTED$1.5M
Net-to-Gross HCRIS18.7%
Distress Probability ML39.8%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
82
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -7.5% places it below the state median. Among 82 size-comparable peers (124-498 beds), the median margin is -8.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (124-498), prioritizing same-state peers. 82 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PAOLI HOSPITAL (Target)PA249$383.3M-7.5%
PRESBYTERIAN MEDICAL CENTERPA328$988.5M-18.9%
UPMC MAGEE-WOMENS HOSPITALPA347$910.8M-23.9%
ALBERT EINSTEIN MEDICAL CENTERPA407$861.3M-20.9%
UPMC CHILDRENS HOSPITAL OF PGHPA317$816.7M-2.5%
GEISINGER WYOMING VALLEY MED CPA309$782.7M5.9%
WESTERN PENNSYLVANIA HOSPITALPA255$776.4M11.1%
PENNSYLVANIA HOSPITAL OF UPHSPA425$739.0M-8.8%
LANKENAU MEDICAL CENTERPA370$621.6M-16.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $28.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$8.0M+210bp18mo
Cost to Collect4.5%2.5%$7.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$7.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$4.7M+122bp9mo
Clean Claim Rate88.0%96.0%$245K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$8.0M
Cost to Collect
$7.7M
Denial Rate Reduction
$7.6M
A/R Days Reduction
$4.7M
Clean Claim Rate
$245K
Total EBITDA Uplift$28.2M
Current EBITDA$-28.7M
+ RCM Uplift+$28.2M
Pro Forma EBITDA$-450K
Current Margin-7.5%
Pro Forma Margin-0.1%
WC Released (1x)$14.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-44.1M$93.1M0.00x-100.0%
Base (11x exit)10.0x11.0x$-44.1M$88.0M0.00x-100.0%
Bull Case9.0x11.0x$-39.7M$166.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-39.7M$170.3M0.00x-100.0%
Bear Case11.0x10.0x$-48.5M$-33.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-48.5M$-52.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 82 hospitals with 124-498 beds
  • Same-state prioritization (n=83)
  • Comp margins: P25=-17.9% / P50=-8.8% / P75=-1.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.